NYSE:MRKPharmaceuticals
A Fresh Look at Merck’s (MRK) Valuation After Major Regulatory and Clinical Pipeline Milestones
Merck (MRK) is making waves this week as the company announced a series of meaningful regulatory and clinical updates. Highlights include new FDA and European approvals, as well as encouraging clinical results for important pipeline drugs.
See our latest analysis for Merck.
Merck’s recent string of regulatory wins and positive clinical trial results has caught investors’ attention, with momentum clearly building. Its 1-month share price return is an impressive 11.7%, while the stock has...